106 related articles for article (PubMed ID: 2905665)
1. Hindlimb paralytic effects of prodynorphin-derived peptides following spinal subarachnoid injection in rats.
Long JB; Martinez-Arizala A; Echevarria EE; Tidwell RE; Holaday JW
Eur J Pharmacol; 1988 Aug; 153(1):45-54. PubMed ID: 2905665
[TBL] [Abstract][Full Text] [Related]
2. Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory and autonomic function.
Long JB; Petras JM; Mobley WC; Holaday JW
J Pharmacol Exp Ther; 1988 Sep; 246(3):1167-74. PubMed ID: 2901487
[TBL] [Abstract][Full Text] [Related]
3. Neurologic deficits and neuronal injury in rats resulting from nonopioid actions of the delta opioid receptor antagonist ICI 174864.
Long JB; Petras JM; Holaday JW
J Pharmacol Exp Ther; 1988 Mar; 244(3):1169-77. PubMed ID: 2908046
[TBL] [Abstract][Full Text] [Related]
4. Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. I. Injection procedures modify pharmacological responses.
Long JB; Mobley WC; Holaday JW
J Pharmacol Exp Ther; 1988 Sep; 246(3):1158-66. PubMed ID: 2901486
[TBL] [Abstract][Full Text] [Related]
5. Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action.
Faden AI; Jacobs TP
Br J Pharmacol; 1984 Feb; 81(2):271-6. PubMed ID: 6142741
[TBL] [Abstract][Full Text] [Related]
6. Dynorphin A-induced rat hindlimb paralysis and spinal cord injury are not altered by the kappa opioid antagonist nor-binaltorphimine.
Long JB; Rigamonti DD; de Costa B; Rice KC; Martinez-Arizala A
Brain Res; 1989 Sep; 497(1):155-62. PubMed ID: 2571391
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the analgesic and paralytic effects induced by intrathecal dynorphin a in rats.
Xue JC; Yu YX; Han JS; Jen MF
Int J Neurosci; 1995 May; 82(1-2):83-93. PubMed ID: 7591518
[TBL] [Abstract][Full Text] [Related]
8. Hindlimb paralytic effects of arginine vasopressin and related peptides following spinal subarachnoid injection in the rat.
Long JB; Martinez-Arizala A; Rigamonti DD; Holaday JW
Peptides; 1988; 9(6):1335-44. PubMed ID: 3247252
[TBL] [Abstract][Full Text] [Related]
9. 1-Aminocyclopropanecarboxylic acid protects against dynorphin A-induced spinal injury.
Long JB; Skolnick P
Eur J Pharmacol; 1994 Aug; 261(3):295-301. PubMed ID: 7813551
[TBL] [Abstract][Full Text] [Related]
10. Regulation of striatonigral prodynorphin peptides by dopaminergic agents.
Trujillo KA; Day R; Akil H
Brain Res; 1990 Jun; 518(1-2):244-56. PubMed ID: 1975215
[TBL] [Abstract][Full Text] [Related]
11. Endogenous opioids in spinal cord injury: a critical evaluation.
Long JB; Martinez-Arizala A; Petras JM; Holaday JW
Cent Nerv Syst Trauma; 1986; 3(4):295-315. PubMed ID: 2884046
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal dynorphin A (1-13) and (3-13) reduce spinal cord blood flow by non-opioid mechanisms.
Long JB; Kinney RC; Malcolm DS; Graeber GM; Holaday JW
NIDA Res Monogr; 1986; 75():524-6. PubMed ID: 2893280
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between motor paralysis and neurotoxicity induced by intrathecal dynorphin A (1-17) in rats].
Cui CL; Wu LZ; Han JS
Yao Xue Xue Bao; 1997; 32(2):85-9. PubMed ID: 11243205
[TBL] [Abstract][Full Text] [Related]
14. Dynorphin A-induced rat spinal cord injury: evidence for excitatory amino acid involvement in a pharmacological model of ischemic spinal cord injury.
Long JB; Rigamonti DD; Oleshansky MA; Wingfield CP; Martinez-Arizala A
J Pharmacol Exp Ther; 1994 Apr; 269(1):358-66. PubMed ID: 7909561
[TBL] [Abstract][Full Text] [Related]
15. Antinociception and paralysis induced by intrathecal dynorphin A.
Herman BH; Goldstein A
J Pharmacol Exp Ther; 1985 Jan; 232(1):27-32. PubMed ID: 2856940
[TBL] [Abstract][Full Text] [Related]
16. Opioid receptor selectivity of dynorphin gene products.
James IF; Fischli W; Goldstein A
J Pharmacol Exp Ther; 1984 Jan; 228(1):88-93. PubMed ID: 6141278
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effects of dynorphins through nonopioid intracellular mechanisms.
Tan-No K; Cebers G; Yakovleva T; Hoon Goh B; Gileva I; Reznikov K; Aguilar-Santelises M; Hauser KF; Terenius L; Bakalkin G
Exp Cell Res; 2001 Sep; 269(1):54-63. PubMed ID: 11525639
[TBL] [Abstract][Full Text] [Related]
18. Ontogenetic development of the pro-enkephalin B (= pro-dynorphin) opioid peptide system in the rat pituitary.
Seizinger BR; Liebisch DC; Grimm C; Herz A
Neuroendocrinology; 1984 Nov; 39(5):414-22. PubMed ID: 6151128
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal dynorphin A1-13 and dynorphin A3-13 reduce rat spinal cord blood flow by non-opioid mechanisms.
Long JB; Kinney RC; Malcolm DS; Graeber GM; Holaday JW
Brain Res; 1987 Dec; 436(2):374-9. PubMed ID: 2893653
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptides in spinal cord injury: comparative experimental models.
Faden AI; Jacobs TP; Smith GP; Green B; Zivin JA
Peptides; 1983; 4(5):631-4. PubMed ID: 6657511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
